Disease-modifying treatments for primary autoimmune haemolytic anaemia

CONCLUSIONS: Available literature on the effectiveness of immunomodulatory therapy for primary AIHA is restricted to comparison between rituximab plus glucocorticoid and glucocorticoid alone, in patients with newly diagnosed warm AIHA, calling for need for additional studies. The current result suggests that combinatory therapy with rituximab and glucocorticoid may increase the rate of complete haematological response over glucocorticoid monotherapy.PMID:33786812 | DOI:10.1002/14651858.CD012493.pub2

Source: Cochrane Database of Systematic Reviews - March 31, 2021 Category: General Medicine Authors: Anthony Pak-Yin Liu Daniel Kl Cheuk Source Type: research